$EQ
Equillium, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021015103 Filed on March 24, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.920M $2.400M $2.170M
YoY Change 6.18% 10.6% 26.9%
% of Gross Profit
Research & Development $5.880M $7.170M $5.450M
YoY Change 24.95% 31.56% 116.27%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $0.00
YoY Change 100.0% -100.0%
% of Gross Profit
Operating Expenses $8.695M $8.970M $7.616M
YoY Change 16.68% 17.78% 80.13%
Operating Profit -$8.695M
YoY Change 16.68%
Interest Expense -$250.0K -$220.0K $20.00K
YoY Change 400.0% -1200.0% -102.63%
% of Operating Profit
Other Income/Expense, Net -$296.0K $280.0K $30.00K
YoY Change -23.12% 833.33%
Pretax Income -$8.990M -$8.920M -$7.570M
YoY Change 14.67% 17.83% 51.7%
Income Tax
% Of Pretax Income
Net Earnings -$8.991M -$8.918M -$7.567M
YoY Change 14.73% 17.85% 51.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$328.9K -$360.1K -$435.6K
COMMON SHARES
Basic Shares Outstanding 29.04M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.1M $82.16M $53.14M
YoY Change 118.31% 54.61% -19.37%
Cash & Equivalents $50.86M $23.98M $13.22M
Short-Term Investments $53.22M $58.18M $39.92M
Other Short-Term Assets $2.500M $3.000M $2.300M
YoY Change 19.05% 30.43% 91.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $106.6M $85.17M $55.43M
YoY Change 113.99% 53.66% -17.39%
LONG-TERM ASSETS
Property, Plant & Equipment $223.0K $239.0K $93.00K
YoY Change 150.56% 156.99% 45.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $15.00K $15.00K
YoY Change 0.0%
Total Long-Term Assets $223.0K $254.0K $108.0K
YoY Change 150.56% 135.19% 68.75%
TOTAL ASSETS
Total Short-Term Assets $106.6M $85.17M $55.43M
Total Long-Term Assets $223.0K $254.0K $108.0K
Total Assets $106.8M $85.43M $55.54M
YoY Change 114.06% 53.82% -17.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.324M $2.766M $1.873M
YoY Change 29.04% 47.68% 67.38%
Accrued Expenses $2.593M $2.813M $2.010M
YoY Change 35.76% 39.95% 121.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.500M $1.666M
YoY Change
Total Short-Term Liabilities $7.417M $7.245M $3.883M
YoY Change 99.87% 86.58% 91.47%
LONG-TERM LIABILITIES
Long-Term Debt $7.506M $8.275M $9.681M
YoY Change -22.98% -14.52%
Other Long-Term Liabilities $35.00K $54.00K $127.0K
YoY Change -67.59% -57.48% -36.5%
Total Long-Term Liabilities $7.541M $8.329M $9.808M
YoY Change -23.47% -15.08% 4804.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.417M $7.245M $3.883M
Total Long-Term Liabilities $7.541M $8.329M $9.808M
Total Liabilities $14.96M $15.57M $13.69M
YoY Change 10.27% 13.75% 514.5%
SHAREHOLDERS EQUITY
Retained Earnings -$79.92M -$70.93M -$41.11M
YoY Change 63.26% 72.52% 165.03%
Common Stock $172.1M $141.1M $82.94M
YoY Change 102.84% 70.1% 3.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $91.88M $69.85M $41.85M
YoY Change
Total Liabilities & Shareholders Equity $106.8M $85.43M $55.54M
YoY Change 114.06% 53.82% -17.31%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2019 Q4
OPERATING ACTIVITIES
Net Income -$8.991M -$8.918M -$7.567M
YoY Change 14.73% 17.85% 51.58%
Depreciation, Depletion And Amortization $20.00K $20.00K $0.00
YoY Change 100.0% -100.0%
Cash From Operating Activities -$7.944M -$8.250M -$9.030M
YoY Change 24.71% -8.64% 135.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K -$10.00K
YoY Change -100.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities $4.860M -$17.01M -$5.310M
YoY Change -62.67% 220.34% -85.8%
Cash From Investing Activities $4.860M -$17.03M -$5.330M
YoY Change -62.63% 219.51% -85.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.96M 20.00K -100.0K
YoY Change 3766.32% -120.0% -100.15%
NET CHANGE
Cash From Operating Activities -7.944M -8.250M -9.030M
Cash From Investing Activities 4.860M -17.03M -5.330M
Cash From Financing Activities 29.96M 20.00K -100.0K
Net Change In Cash 26.88M -25.26M -14.46M
YoY Change 263.48% 74.69% -161.43%
FREE CASH FLOW
Cash From Operating Activities -$7.944M -$8.250M -$9.030M
Capital Expenditures $0.00 -$30.00K -$10.00K
Free Cash Flow -$7.944M -$8.220M -$9.020M
YoY Change 24.42% -8.87% 135.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
37120000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-26727000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-29548000
CY2019 us-gaap Operating Expenses
OperatingExpenses
26727000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10164000
CY2020 us-gaap Operating Expenses
OperatingExpenses
29548000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23982000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
58181000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3011000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
85174000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
239000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39924000
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2288000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
55431000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
93000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2020 dei City Area Code
CityAreaCode
858
CY2020 dei Local Phone Number
LocalPhoneNumber
412-5302
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13219000
CY2020Q4 us-gaap Assets
Assets
85428000
CY2019Q4 us-gaap Assets
Assets
55539000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2766000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1873000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2813000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2010000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1666000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7245000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3883000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8275000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29040270
CY2020Q2 dei Entity Public Float
EntityPublicFloat
18800000
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Entity File Number
EntityFileNumber
001-38692
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1554746
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9681000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
54000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
127000
CY2020Q4 us-gaap Liabilities
Liabilities
15574000
CY2019Q4 us-gaap Liabilities
Liabilities
13691000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
141074000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82938000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-297000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70925000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41112000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
69854000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
41848000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85428000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
44000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-277000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-318000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
156000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
73000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55539000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24753102
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17425654
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24753102
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17425654
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19384000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17640000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9087000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
1099000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
279000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
476000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1391000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
358000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-41000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30131000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25584000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20355534
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17378096
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
64935000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
42000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
74000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
266000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
69000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
35717000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
252000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3817000
CY2020 us-gaap Profit Loss
ProfitLoss
-29813000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
45000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3817000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
360000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
20000
CY2020 eq Non Cash Consulting Expense
NonCashConsultingExpense
81000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
260000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
65000
CY2020 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
13000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-104000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
382000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
491000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1115000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
894000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
775000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
82200000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
852000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1053000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24624000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22949000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
202000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55510000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
54619000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
300000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2543745
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1901521
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2019 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
52527000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18592000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2166000
CY2019 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9881000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
156000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
42000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
69000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53945000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9836000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-10000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10763000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15289000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13219000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28508000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23982000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
839000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
142000
CY2019 eq Fair Value Of Common Stock Warrants In Connection With Issuance Of Notes Payable
FairValueOfCommonStockWarrantsInConnectionWithIssuanceOfNotesPayable
266000
CY2019 eq Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
50000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2020Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Three
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearThree
3333000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Significant estimates in the Company&#8217;s consolidated financial statements relate to clinical trial accruals and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Off-Balance Sheet Risk</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#8217;s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p>
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
CY2020Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Next Twelve Months
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1667000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1475093
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39875000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
55000
CY2020 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
58181000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
39924000
CY2020Q4 us-gaap Notes Payable
NotesPayable
9900000
CY2019Q4 us-gaap Notes Payable
NotesPayable
9700000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
74000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29000
CY2020 us-gaap Depreciation
Depreciation
45000
CY2019 us-gaap Depreciation
Depreciation
23000
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1870000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1215000
CY2020Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
493000
CY2019Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
442000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
307000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
267000
CY2020Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
72000
CY2019Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
15000
CY2020Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Two
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearTwo
3333000
CY2020Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFee
10450000
CY2020Q4 eq Unaccreted Liability For Final Payment Fee
UnaccretedLiabilityForFinalPaymentFee
274000
CY2020Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Four
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFour
2117000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
235000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
9941000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1666000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8275000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6600000
CY2020 eq Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2037
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
286000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4100000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6261000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
221000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15570000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1400000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.11
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.65
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6600000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2020Q2 eq Number Of Non Management Directors
NumberOfNonManagementDirectors
2
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3817000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2252000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0065
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0223
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8956
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9358
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 eq Dividends Paid On Common Stock
DividendsPaidOnCommonStock
0
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4195805
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3218710
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
153000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
26000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
179000
CY2020 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29420000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23167000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-393000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2433000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-29813000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-25600000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5376000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
97000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
276000
CY2020 eq Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
15000
CY2019 eq Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
54000
CY2020 eq Income Tax Reconciliation Federal Research And Orphan Drug Credits
IncomeTaxReconciliationFederalResearchAndOrphanDrugCredits
445000
CY2019 eq Income Tax Reconciliation Federal Research And Orphan Drug Credits
IncomeTaxReconciliationFederalResearchAndOrphanDrugCredits
684000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
367000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-158000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6227000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5887000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12338000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7212000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1940000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1227000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
118000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
129000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
888000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
188000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8976000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8977000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15564000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
6348000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6439000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
6324000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
7616000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
53000000
CY2020 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Federal net operating losses generated after December 31, 2017 carryover indefinitely and may generally be used to offset up to 80% of future taxable income.
CY2020 eq Tax Credit Carryforward Expiration Year
TaxCreditCarryforwardExpirationYear
2037
CY2020 eq Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2020 eq Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
360000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
89000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1988000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
319000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
271000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2667000
CY2020 eq Carryback Period Of Certain Losses Period
CarrybackPeriodOfCertainLossesPeriod
P5Y
CY2020 eq Suspension Of Limitation Imposed By Tax Cuts And Jobs Act Percent
SuspensionOfLimitationImposedByTaxCutsAndJobsActPercent
0.80
CY2019 eq Suspension Of Limitation Imposed By Tax Cuts And Jobs Act Percent
SuspensionOfLimitationImposedByTaxCutsAndJobsActPercent
0.80
CY2018 eq Suspension Of Limitation Imposed By Tax Cuts And Jobs Act Percent
SuspensionOfLimitationImposedByTaxCutsAndJobsActPercent
0.80
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
7452000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6610000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
6516000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
8970000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7837000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6461000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6597000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-8918000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5950000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6069000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6014000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7567000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44

Files In Submission

Name View Source Status
0001564590-21-015103-index-headers.html Edgar Link pending
0001564590-21-015103-index.html Edgar Link pending
0001564590-21-015103.txt Edgar Link pending
0001564590-21-015103-xbrl.zip Edgar Link pending
eq-10k_20201231.htm Edgar Link pending
eq-20201231.xml Edgar Link completed
eq-20201231.xsd Edgar Link pending
eq-20201231_cal.xml Edgar Link unprocessable
eq-20201231_def.xml Edgar Link unprocessable
eq-20201231_lab.xml Edgar Link unprocessable
eq-20201231_pre.xml Edgar Link unprocessable
eq-ex1028_993.htm Edgar Link pending
eq-ex1029_1260.htm Edgar Link pending
eq-ex231_17.htm Edgar Link pending
eq-ex311_18.htm Edgar Link pending
eq-ex312_10.htm Edgar Link pending
eq-ex321_16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
glhlosbgthrh000001.jpg Edgar Link pending
glhlosbgthrh000002.jpg Edgar Link pending
glhlosbgthrh000003.jpg Edgar Link pending
glhlosbgthrh000004.jpg Edgar Link pending
glhlosbgthrh000005.jpg Edgar Link pending
glhlosbgthrh000006.jpg Edgar Link pending
glhlosbgthrh000007.jpg Edgar Link pending
glhlosbgthrh000008.jpg Edgar Link pending
glhlosbgthrh000009.jpg Edgar Link pending
glhlosbgthrh000010.jpg Edgar Link pending
glhlosbgthrh000011.jpg Edgar Link pending
glhlosbgthrh000012.jpg Edgar Link pending
glhlosbgthrh000013.jpg Edgar Link pending
glhlosbgthrh000014.jpg Edgar Link pending
goh4vj1cq2tf000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending